Dabigatran Etexilate Mesylate CAS 872728-81-9

Product Description:

Product Name: Dabigatran Etexilate Mesylate CAS NO: 872728-81-9

Synonyms:

dabigatran etexilate methanesulfonate;

Ethyl N-[(2-{[(4-{N-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-2-pyridinyl-β-alaninate methanesulfonate (1:1);

Chemical & Physical Properties:

Appearance : white to off-White powder

Assay :≥99.0%

Dabigatran etexilate mesylate is a direct thrombin inhibitor used in clinical practice and a new type of oral anticoagulant. Its mechanism of action is to inhibit the formation of fibrin through reversible and strong competition to bind to the fibrin specific binding site of thrombin, thereby inhibiting the formation of thrombus.

Dabigatran etexilate mesylate is a prodrug of dabigatran, which is converted into active dabigatran after metabolism in the body. Compared with warfarin, dabigatran etexilate mesylate does not require frequent monitoring of coagulation function and dosage adjustment during the treatment process, and there is less interaction between drugs and is not affected by eating, thereby improving the patient's medication compliance.

Everyone must know that warfarin is currently the main drug used to prevent stroke and systemic embolism in patients with atrial fibrillation, and it has an irreplaceable position in the anticoagulation therapy of patients with atrial fibrillation. Warfarin has always been considered as the antithrombotic therapy in this field. gold standard. However, in clinical applications, it has been found that warfarin interacts with many drugs and diets, such as quinolone and macrolide antibiotics. It is often impossible to guarantee that its dose will always be maintained within the therapeutic window and increase the risk of bleeding. In order to ensure the safety of medication, it is necessary to routinely monitor blood coagulation function and adjust medication dosage.

Dabigatran etexilate is another new oral anticoagulant approved by the US Food and Drug Administration after warfarin. It is a non-peptide thrombin inhibitor that specifically and selectively blocks thrombin (Free or combined) activity to exert anticoagulant effect. It can be taken orally, is potent, does not require special medication monitoring, and has less drug interactions. It is a major advance in the field of anticoagulation therapy and the field of potentially fatal thrombosis prevention, and it is a milestone. After oral absorption through the gastrointestinal tract, it is transformed into dabigatran with direct anticoagulant activity in the body. By binding to the fibrin specific binding site of thrombin, it prevents fibrinogen from cleaving into fibrin, thereby blocking blood clotting The final step of the waterfall network and thrombosis. Dabigatran can also dissociate from the fibrin-thrombin conjugate and exert a reversible anticoagulant effect.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.